Assessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failure

Página do item simplificado
dc.contributor.authorBregagnollo, Edson Antônio [UNESP]
dc.contributor.authorFortes, Adjair Humberto [UNESP]
dc.contributor.authorCicogna, Antonio Carlos [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T15:18:26Z
dc.date.available2014-05-20T15:18:26Z
dc.date.issued1999-02-01
dc.description.abstractOBJECTIVE: To assess the hemodynamic and vasodilating effects of milrinone lactate (ML) in patients with dilated cardiomyopathy (DCM) and New York Heart Association (NYHA) class III and IV heart failure. METHODS: Twenty patients with DCM and NYHA class III and IV heart failure were studied. The hemodynamic and vasodilating effects of ML, administered intravenously, were evaluated. The following variables were compared before and during drug infusion: cardiac output (CO) and cardiac index (CI); pulmonary capillary wedge pressure (PCWP); mean aortic pressure (MAP); mean pulmonary artery pressure (MPAP); mean right atrial pressure (MRAP); left ventricular systolic and end-diastolic pressures (LVSP and LVEDP, respectively); peak rate of left ventricular pressure rise (dP/dt); systemic vascular resistance (SVR); pulmonary vascular resistance (PVR); and heart rate (HR). RESULTS: All patients showed a significant improvement of the analysed parameters of cardiac performance with an increase of CO and CI; a significant improvement in myocardial contractility (dP/dt) and reduction of the LVEDP; PCWP; PAP; MAP; MRAP; SVR; PVR. Were observed no significant increase in HR occurred. CONCLUSION: Milrinone lactate is an inotropic dilating drug that, when administered intravenously, has beneficial effects on cardiac performance and myocardial contractility. It also promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure.en
dc.description.affiliationUNESP Faculdade de Medicina de Botucatu
dc.description.affiliationUnespUNESP Faculdade de Medicina de Botucatu
dc.format.extent149-160
dc.identifierhttp://dx.doi.org/10.1590/S0066-782X1999000200003
dc.identifier.citationArquivos Brasileiros de Cardiologia. Sociedade Brasileira de Cardiologia - SBC, v. 72, n. 2, p. 149-160, 1999.
dc.identifier.doi10.1590/S0066-782X1999000200003
dc.identifier.fileS0066-782X1999000200003.pdf
dc.identifier.issn0066-782X
dc.identifier.lattes9418970103564137
dc.identifier.scieloS0066-782X1999000200003
dc.identifier.urihttp://hdl.handle.net/11449/30896
dc.language.isoeng
dc.publisherSociedade Brasileira de Cardiologia (SBC)
dc.relation.ispartofArquivos Brasileiros de Cardiologia
dc.relation.ispartofjcr1.318
dc.rights.accessRightsAcesso aberto
dc.sourceSciELO
dc.subjectheart failureen
dc.subjectinotropic agentsen
dc.subjectmilrinoneen
dc.titleAssessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failureen
dc.typeArtigo
unesp.author.lattes9418970103564137[3]
unesp.author.orcid0000-0002-4402-6523[3]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0066-782X1999000200003.pdf
Tamanho:
422.28 KB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Clínica Médica - FMB